Update: PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) receive FDA approval for metastatic prostate cancer

The following studies are looking at PARP inhibitors and similar agents for treating people with advanced prostate cancer.  

• NCT04592237: Chemotherapy, Immunotherapy and PARP Inhibitor for the Treatment of Metastatic Aggressive Variant Prostate Cancer. This study will look at how well the combination of chemotherapy drugs (such as cabazitaxel and carboplatin), a PARP inhibitors (niraparib), and an immunotherapy agents (cetrelimab) works for treating people with a rare type of prostate cancer known as aggressive variant prostate cancer (AVPC). 
• NCT04821622: TALAPRO-3: A Clinical Trial in Men with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and DNA Damage Repair (DDR) Gene Alterations. TALAPRO-3 is a trial for men who have been diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) which means that the tumor has spread to other parts of the body but it is still sensitive to hormone therapies.  
• NCT05005728: XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer. This study will look at the safety and clinical activity of the drug XmAb20717 alone or in combination with standard-of-care anticancer therapies in patients with metastatic castration-resistant prostate cancer who have been treated with at least 2 prior lines of treatment.
• NCT03012321: Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects. This phase II study in men with metastatic castration resistant prostate cancer (mCRPC) is open to men with a PALB2 or other mutation.
• NCT04455750: A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy. This trial is evaluating the benefit of rucaparib and enzalutamide combination therapy versus enzalutamide alone for the treatment of men with metastatic prostate cancer that has become resistant to testosterone-deprivation therapy.

Other clinical trials for people with prostate cancer can be found here.

Updated: 08/06/2022

The following are studies looking at treatment for people with advanced solid tumors. 

• NCT05169437: PARP inhibitor (niraparib) in patients with inherited or tumor PALB2 mutations in advanced solid tumors (PAVO). PAVO is a Phase II study investigating if the study drug, a PARP inhibitor called niraparib, is safe and effective for certain people who have been diagnosed with an advanced solid tumor with either an inherited or tumor PALB2 mutation.
• NCT02264678: Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents. This is a study of ceralasertib administered orally in combination with chemotherapy regimens and/or novel anti-cancer agents, to patients with advanced cancer. The study is enrolling people with inherited mutations including BRCA1, BRCA2, ATM, RAD51C, RAD51D and people with tumors that are HRD-positive.  
• NCT03162627: Selumetinib and Olaparib in Solid Tumors. The goal of Phase 1 of this clinical research study is to find a tolerable dose combination of selumetinib and olaparib that can be given to people with advanced or recurrent solid tumors. This study is open to people whose cancer stopped responding or progressed on PARP inhibitors.
• NCT04644068: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA). This research is designed to learn if treatment with a new PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors. The study is open to people who have previously been treated with PARP inhibitors.  
• NCT04267939: ATR Inhibitor Plus Niraparib Study in Advanced Solid Tumors and Ovarian Cancer. This study will look at how well how well people with advanced solid tumors respond to treatment with the targeted therapy BAY1895344 in combination with the PARP inhibitor niraparib. This study is open to people with inherited mutations in ATM, BRCA1, BRCA2 and others. Contact the study coordinator for information about eligilibity for people with mutations in other genes. 
• NCT04657068: Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors. This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes linked to DNA damage repair. This study is open to people who have an inherited or acquired BRCA or ATM mutation or people with tumors that are HRD-positive. This study is open to people whose cancer stopped responding or progressed on PARP inhibitors.
• NCT04197713: Olaparib Combined with AZD1775, an Investigational Targeted Therapy for People with Advanced Solid Tumors with Mutations in BRCA1, BRCA2, BRIP1, PALB2 or Others. This study is looking at how well the oral therapy AZD1775 works when combined with the PARP inhibitor Olaparib for treating advanced cancers in people with an inherited or tumor mutation in BRCA1, BRCA2, BRIP1, PALB2 or other genes or biomarkers. The study is open to people who have stopped responding or progressed after treatment with a PARP inhibitor.

Updated: 06/26/2022